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Summary: To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new
direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific
coagulation factors has already entered the market, and new indications for DOA will be released each year over
the next few years. Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA
will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.
In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are
described.Introduction
In multiple clinical situations, coagulation parameters as
the prothrombin time (PT) are checked for safe and ef-
fective treatment with vitamin K anticoagulants [1]. Glo-
bal coagulation assays are performed on a routine base
even after administration of the new direct oral antico-
agulants (DOA), although routine laboratory monitoring
is not required [2,3] for these new drugs as dabigatran,
rivaroxaban or apixaban. Prolongation of clotting times
after DOA administration may raise concerns about the
anticoagulant treatment with DOA. As a result, data
might be misinterpreted; DOA therapy might be discon-
tinued; and another anticoagulant might be started.
Therefore, the main considerable factors for correct la-
boratory test interpretation under DOA treatment have
to be known.
Reason for interference of DOA on coagulation assays
Usually, the time between the addition of a coagulation
activating reagents and the formation of the fibrin clot
is measured. Increasing viscosity in the plasma sample
allows the detection of the end point. Inhibition of Factor
Xa results in inhibiting the formation of thrombin. Throm-
bin itself is needed to format the fibrin clot, which is de-
tected in a coagulation clotting assay. Because rivaroxaban* Correspondence: Helen.Mani@kgu.de
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distribution, and reproduction in any mediumand apixaban are selective direct inhibitors of Factor
Xa and dabiagtran a direct thrombin inhibitor, coagu-
lation clotting assays are influenced by these drugs
(Figure 1).
The in vitro and ex-vivo influence of rivaroxaban and
dabigatran on global and specific coagulation assays are
well described [4-13], since these two new oral anticoagu-
lants are increasingly used for various indications world-
wide. Moreover, apixaban, as second direct oral Factor Xa
inhibitor, has recently received its approval for the preven-
tion of stroke in patients with non-valvular atrial fibrilla-
tion, and its effect on routine and specific coagulation
assays has been analysed, too [14]. As seen in Table 1, co-
agulation clotting assays are influenced by DOA to differ-
ent extends.
The results of the ex-vivo and in-vitro effects of these
new drugs on the coagulation parameters as PT or aPTT
can be used to find out the main considerable factors for
correct interpretation of laboratory test results in pa-
tients under DOA treatment.
The main considerable factors for correct laboratory test
interpretation under DOA treatment
To avoid erroneous interpretation it is important to be
aware of the four main factors that have to be consid-
ered at the same time when coagulation parameters are
measured in plasma with DOA (Figure 2).
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Figure 1 Classical coagulation pathway with clotting assays and targets of DOA.
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assays
Rivaroxaban and apixaban as selective direct inhibitors
of factor Xa, inhibit prothrombinase-bound factor Xa.
Since the PT assay is sensitive to the prothrombinase
complex, the PT is influenced by direct factor XaTable 1 Influence of DOA on different coagulation assays
Influence of DOA on coagulation parameters
PT [INR or sec] ↑ ↑↑↑ ↑↑
aPTT ↑↑↑ ↑↑ ↑
Thrombin Time ↑↑↑↑↑ - -
Fibrinogen (Clauss method) derived Fibrinogen ↓(↓) - -
(↑) ↑ (↑)
Antithrombin FXa-based assay - ↑ ↑
FIIa-based assay ↑ - -
Intrinsic coagulation factors VIII, IX, XI, XII
(based on aPTT)
↓↓ ↓ ↓
Extrinisic coagulation factors II,V,VII,X (based on PT) ↓ ↓↓ ↓↓
Factor XIII -photometric ↓↓ - -
-immunologic - - -
Protein S (clotting) ↑↑ ↑↑ ↑
Free Protein S antigen (immunologic) - - -
(chromogenic) ↑↑ ↑ ↑
- - -
Diluted Russel’s Viper Venom - test ↑ ↑↑↑ ↑↑
Activated Protein C-Ratio (based on aPTT-assay) ↑↑ ↑ ↑
Ecarin Clotting Time ↑↑ - -inhibitors of factor Xa, whereas dabigatran in low doses
has little effect on PT (Figure 3).
As screening assay the aPTT detects abnormalities in ki-
ninogen, prekallikrein, XII, XI, IX, VIII, V, and factor Xa
and thrombin, both targets of rivaroxaban and dabigatran.
A prolongation of aPTT is observed in the presence of in-
creasing doses of dabigatran and –to a much less extend –
with rivaroxaban or apixaban [4,6,8,9,14,15] (Figure 4).
The thrombin time (TT) is used to measure fibrin
polymerisation and is performed by adding a low concen-
tration of thrombin to plasma. Since the TT assay is a di-
rect measurement of thrombin activity, and dabigatran is
a direct thrombin inhibitor, the TT assay is highly sensitive
to dabigatran Table 1. TT is reported to response even at
lowest dabigatran plasma concentrations [8,9,11,15]. Because
rivaroxaban and apixaban do not directly inhibit thrombin,
no influence of both drugs on TT is reported [7,11,14].
Clinicians should find out which drug was adminis-
trated to the patient before routine coagulation parame-
ters are checked and interpreted.
2. Dependence on the drug pharmacokinetics and drug
concentration.
More drug concentration in plasma-more effect on co-
agulation assays
Dabigatran, rivaroxaban and apixaban have predictable
pharmacokinetic profiles with plasma concentrations
reaching a peak within 2-4 hours after intakeand terminal
half-lives of 7-17 hours. Corresponding to the half-lives, a
decline of plasma concentration is observed over time;
drug
time of latest drug intake
test method
test reagent
Knowledge of influencing parameters
Figure 2 The four main considerable factors for correct laboratory test interpretation under DOA treatment.
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rameters also decrease over time. Since there is this direct
correlation between drug concentration and its effect on
clotting assays, it is of prime importance to know the time
of drug intake in relation to blood sampling as can be seen
for example in the values of PT and aPTT in Figures 3
and 4.Prothro
Effect of dabigatran and rivaroxaban
drug administration an
Dabigatran
Figure 3 Effect of dabigatran and rivaroxaban on the prothrombin timeThe prolongations of PT and aPTT are short lived. Two
to three hours after DOA administration, a significant
prolongation expressed in seconds of PT or aPTT will be
observed. The minimum effect of DOA is observed di-
rectly before drug intake.
Therefore it is recommended, that laboratory monito-
ring of coagulation factors, if needed, should be performedmbin Time
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Figure 4 Effect of dabigatran and rivaroxaban on the activated partial thromboplastin time in dependence of drug administration
and reagent.
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of drugs low.
3. Dependence on the test method used in the laboratory.
Different test methods – different test results
The knowledge of the test method used for determin-
ation of the coagulation parameter is important for cor-
rect interpretation of results. Two examples:
a. Antithrombin determination can be performed using
test systems, in which the plasma sample is incubated
either with an excess of thrombin, or with an excess of
factor Xa. Antithrombin levels based on addition of
factor Xa are measured falsely high when rivaroxaban
plasma samples are investigated. No influence is
observed by rivaroxaban, when determination of
antithrombin levels is based on thrombin [7].
b. The frequently used method for the determination of
fibrinogen as one of the routine parameters in
coagulation testing is the method according to Clauss.
This method is based on the addition of an excess of
thrombin to plasma. Rivaroxaban, does not influence
fibrinogen assays based on the Clauss method because it
does not inhibit thrombin activity [7]. Another method
for measurement of fibrinogen is the PT derived
fibrinogen assay as widely used alternative method, due
to the fact that the total increase of turbidity during PT
is directly proportional to the concentration of fibrinogen.
The effect of rivaroxaban on PT derived fibrinogenassays varies significantly depending on the drug
concentration and the PT reagent used for this assay [7].
Therefore, clinicians should to be aware of various ef-
fects of DOA depending on the test method. Dabigatran
as direct thrombin inhibitor, influences fibrinogen assays
based on Clauss method at increasing drug concentrations
and test reagents- and to much less extend PT derived fi-
brinogen assays [16].
4. Dependence on the test reagent used in the
laboratory.
Different test reagents – different influence of DOA
Several ex-vivo and in-vitro studies have shown that the
prolongation of PT and aPTT depends on the different
sensitivities of the thromboplastin reagents and APTT re-
agents used for the assay [6-12]. For example: different
thromboplastin reagents exhibit different sensitivities to
rivaroxaban at the same concentrations. A sensitive re-
agent such as Neoplastin Plus® has been significantly influ-
enced by rivaroxaban while hardly any effect is observed
on Innovin® (see Figure 2).
Therefore, clinicians should also be aware of the differ-
ent sensitivities of DOA on various test reagents within
one test parameter.
Conclusion
In emergency situations like acute bleeding the clinicians
could be misled by the results of coagulation tests, which are
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ics of the drug after intake or the type of test assay used.
For correct interpretation of coagulation assays during
DOA treatment, clinicians need to know about the tem-
poral effects of the target specific drugs on coagulation
tests and the pitfalls in the laboratory.
The results of coagulation assays may differ from la-
boratory to laboratory depending on the test reagent and
test method used in the laboratory, making comparisons
between the laboratories difficult.
In future, practical approach in the laboratory is neces-
sary and a comprehensive system of optimal patient care
by exact interpretation of coagulation results under DOA
treatment has to be developed worldwide in future.
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